Loading company…
Matwings Technology uses AI to design and modify proteins for biomedical and other applications.
Matwings Technology provides AI protein design services using its AccelProtein™ model and develops products such as dual-target fusion proteins and DNA polymerases. Its work targets biomedicine and in vitro diagnostics. Based in Shanghai, China, it raised a Series A++ round in July 2026, co-led by Shanghai State-owned Capital Investment Leading Fund and CS Capital, with participation from Golden Vision Capital, Caixin Capital, Shanghai STVC Group, J-Micro, Fortera Capital, Qiming Venture Partners, GSR United Capital, Yonghua Capital, and 3E Bioventures Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in